GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (FRA:PBN0) » Definitions » Shiller PE Ratio

Alterity Therapeutics (FRA:PBN0) Shiller PE Ratio : (As of Jun. 25, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Alterity Therapeutics Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alterity Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Alterity Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alterity Therapeutics Shiller PE Ratio Chart

Alterity Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Alterity Therapeutics Quarterly Data
Jun18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alterity Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Alterity Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alterity Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's Shiller PE Ratio falls into.



Alterity Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Alterity Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Alterity Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/126.3989*126.3989
=0.000

Current CPI (Dec. 2023) = 126.3989.

Alterity Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200806 -28.264 85.071 -41.995
200812 -6.863 85.814 -10.109
200906 -5.845 86.278 -8.563
200912 -3.711 87.578 -5.356
201006 -4.862 88.971 -6.907
201012 -7.162 89.993 -10.059
201106 -4.465 92.129 -6.126
201112 -5.538 92.686 -7.552
201206 -2.962 93.244 -4.015
201212 -6.504 94.730 -8.678
201306 -4.037 95.473 -5.345
201312 -7.746 97.330 -10.059
201406 -4.714 98.352 -6.058
201412 -1.045 99.002 -1.334
201506 -3.754 99.838 -4.753
201509 0.000 100.302 0.000
201512 -2.115 100.673 -2.655
201606 -3.636 100.859 -4.557
201612 -2.842 102.159 -3.516
201706 -2.949 102.809 -3.626
201712 -2.636 104.110 -3.200
201806 -3.350 104.945 -4.035
201812 -3.743 105.967 -4.465
201906 -3.724 106.617 -4.415
201909 0.000 107.174 0.000
201912 -2.417 107.917 -2.831
202006 -3.125 106.246 -3.718
202012 -2.414 108.846 -2.803
202103 0.000 109.496 0.000
202106 -0.952 110.332 -1.091
202109 0.000 111.168 0.000
202112 -1.026 112.654 -1.151
202203 0.000 115.069 0.000
202206 -1.037 117.112 -1.119
202209 0.000 119.248 0.000
202212 -1.261 121.477 -1.312
202303 0.000 123.148 0.000
202306 -0.892 124.170 -0.908
202309 0.000 125.656 0.000
202312 0.000 126.399 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alterity Therapeutics  (FRA:PBN0) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Alterity Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alterity Therapeutics (FRA:PBN0) Business Description

Traded in Other Exchanges
Address
350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Alterity Therapeutics (FRA:PBN0) Headlines

No Headlines